Clinical Trials Directory

Trials / Completed

CompletedNCT03546569

Tumor Cells, Tumor DNA and Immunological Response in Colonic Stent Placement

Circulation Tumor Cells, Tumor DNA and Immunological Response in Relation to Colonic Stent Placement for Malignant Obstruction

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
Zealand University Hospital · Academic / Other
Sex
All
Age
18 Years – 95 Years
Healthy volunteers
Not accepted

Summary

This study aims to investigate levels of circulating cell free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTC) and immunological changes after self-expanding metal stent (SEMS) placement for malignant obstruction in the colon, and interpret these levels in relation to overall- and disease-free survival. Furthermore, we intend to study the opportunity to identify patients with a higher risk of recurrence due to the SEMS placement by monitoring cfDNA and ctDNA-levels, as it may be a potential biomarker to initiate or optimize chemotherapy and thereby ensure a better prognosis for the patients.

Detailed description

Study design This prospective study will include 20 patients undergoing SEMS placement as a bridge to elective surgery at Koege- and Slagelse Hospital. Baseline blood samples will be collected before the procedure. After the procedure blood samples will be collected 1, 4, 12 and 24 hours after SEMS placement. After elective surgery a tumor sample will be collected. Prior to SEMS placement: When potential candidates are admitted to the hospital they will be presented to the study by the relevant surgeon. The investigators will be contacted, when the patient is admitted to hospital.

Conditions

Timeline

Start date
2018-05-01
Primary completion
2020-01-01
Completion
2021-02-01
First posted
2018-06-06
Last updated
2021-02-25

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03546569. Inclusion in this directory is not an endorsement.